PDCD1 and neoplasm: Measurements of tumor volume and weight demonstrated a marked reduction in the Sono@NAT10 group relative to PBS and Sono@NC groups, with the greatest reduction observed under combined treatment with anti‐PD‐1 (CD279) antibody (Figure 8E–G; Figure S9B–D, Supporting Information).